Author

Mykola Pavlovich Kopytsya

Observed names: M Kopytsya, M P Kopytsya, M Y K O L A Kopytsya, M. Kopytsya, M. P. Kopytsia, M. P. Kopytsya, M.P Kopytsya, M.P. Kopytsya, M. P. Kopytsya, M. P. Kopytsya, Mikola Kopytsya, Mykilay Kopytsya, Mykola KOPYTSYA, Mykola Kopytsya, Mykola P Kopytsya, Mykola P. Kopytsya

Institutions: L.T. Malaya National Therapy Institute of the National Academy of Medical Sciences of Ukraine, National Academy of Medical Sciences of Ukraine

Observed institutions: Zaporizhzhia State Medical and Pharmaceutical University, L.T. Malaya National Therapy Institute of the National Academy of Medical Sciences of Ukraine, Duke Medical Center, National Academy of Medical Sciences of Ukraine, University of Glasgow, V. N. Karazin Kharkiv National University

ORCID: 0000-0003-4779-7347

Observed ORCID: 0000-0003-4779-7347

OpenAlex ID: A5014311341

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

2019 · Kausik K Ray, Helen M Colhoun, et al. · The Lancet Diabetes & Endocrinology · 337

Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

2016 · Sean D. Pokorney, Jonathan P. Piccini, et al. · Journal of the American Heart Association · 208

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

2021 · Gregory G. Schwartz, Michael Szarek, et al. · Journal of the American College of Cardiology · 161

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

2021 · Hiddo J L Heerspink, C David Sjöström, et al. · European Heart Journal · 128

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

2022 · Emil Hagström, P. Gabriel Steg, et al. · Circulation · 123

A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

2021 · Hiddo J.L. Heerspink, David Cherney, et al. · Kidney International · 98

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

2021 · Gregory G. Schwartz, Michael Szarek, et al. · Diabetes Care · 40

Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES

2025 · P. Gabriel Steg, Michael Szarek, et al. · Circulation · 31

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

2024 · Shaun G Goodman, Philippe Gabriel Steg, et al. · European Heart Journal - Cardiovascular Pharmacotherapy · 28

Lower Circulating Cell-Free Mitochondrial DNA Is Associated with Heart Failure in Type 2 Diabetes Mellitus Patients

2023 · Tetiana Berezina, Mykola Kopytsya, et al. · Cardiogenetics · 10

Removal of the Tumor Thrombus from the Right Atrium without Extracorporeal Circulation: Emphasis on the Displacement of the Tumor Apex

2020 · D. V. Shchukin, V. N. Lesovoy, et al. · Advances in Urology · 9

Features of the cardiovascular system lesion in patients with COVID-19

2020 · Mykola Kopytsya, Iuliia Rodionova, et al. · ScienceRise Medical Science · 4

Short-term clinical outcomes in patients with acute myocardial infarction after successful percutaneous coronary revascularization: the role of promoter polymorphism of the endothelial nitric oxide synthase gene

2019 · Olga V. Petyunina, Mykola P. Kopytsya, et al. · Biomedical Research and Therapy · 4

Macrophage migration inhibitory factor (MIF): can functional insights pave the way for future therapeutics in cardiovascular diseases?

2025 · Tatyana Storozhenko, Olga Petyunina, et al. · Expert Opinion on Therapeutic Targets · 3

The Role of Biomarker Macrophage Migration Inhibitory Factor in Cardiac Remodeling Prediction in Patients With St-segment Elevation Myocardial Infarction

2023 · Iryna R. Vyshnevska, Tatyana Storozhenko, et al. · Wiadomości Lekarskie · 3

Biomarker Sst2 as an Early Predictor of Acute Renal Injury in Patients With St-segment Elevation Acute Myocardial Infarction.

2020 · I Vyshnevska, M Kopytsya, et al. · PubMed · 3

Prediction of one-year adverse clinical outcomes by macrophage migration inhibitory factor in stemi patients

2022 · Iryna Vyshnevska, Tatyana Storozhenko, et al. · EUREKA Health Sciences · 2

Brain-derived neurotrophic factor gene polymorphism in post-ST-elevation myocardial infarction patients undergoing primary percutaneous intervention

2020 · Olga V. Petyunina, Mykola P. Kopytsya, et al. · Biomedical Research and Therapy · 2

Subclinical Emotional Distress Predicts 6-month Clinical Outcomes After ST-segment Elevation Myocardial Infarction

2020 · Olga V Petyunina, Mykola P Kopytsya, et al. · Future Cardiology · 2

The predictive value of vascular endothelial growth factor-A gene polymorphism for clinical outcomes among acute ST-segment elevation myocardial infarction patients: A single center prospective study

2020 · Inna M. Kutia, Mykola P. Kopytsya, et al. · Biomedical Research and Therapy · 2

The Role of Val66Met Single Nucleotide Polymorphism in Brain-Derived Neurotropic Factor Gene in Prediction of Adverse Outcomes After ST-segment Elevation Myocardial Infarction

2019 · Olga V. Petyunina, Mykola P. Kopytsya, et al. · Heart and Mind · 2

Macrophage Inhibitory Factor Predicted Late Cardiac Remodeling in Acute Myocardial Infarction Patients Underwent Successful Percutaneous Coronary Intervention

2019 · Olga V Petyunina, Mykola P Kopytsya, et al. · 2

Elevated levels of circulating soluble ST2 at discharge predict late adverse ventricular remodeling in patients with ST-segment elevation myocardial infarction

2018 · Olga V. Petyunina, Mykola P. Kopytsya, et al. · Biomedical Research and Therapy · 2

Growth Differentiation Factor 15 as a Prognostic Marker of Chronic Heart Failure Progression in Long-term Follow-up After Acute Coronary Syndrome.

2017 · M Kopytsya, I Vyshnevska, et al. · PubMed · 2

Prognostic value of echocardiographic parameters in predicting major adverse cardiac events one year following st-segment elevation myocardial infarction

2024 · I Vishnevskaya, O Petyunina, et al. · European Heart Journal · 1

Works count: 91

Citation count: 1,222

H-index: 10

I10-index: 10